MONTREAL, March 28, 2024 - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies, is poised to make a significant impact in the field of cancer research with its advanced SORT1+ Technology platform. The company has announced its participation in the highly anticipated American Association for Cancer Research (AACR) Annual Meeting 2024, during which it will present two posters showcasing the potential of its platform.
The SORT1+ Technology platform is designed to target and deliver therapeutic agents specifically to cancer cells, leading to improved efficacy and reduced toxicity compared to traditional treatment approaches. Leveraging this innovative platform, Theratechnologies has developed novel camptothecin-peptide conjugates and its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), as potential groundbreaking anticancer treatments.
With the AACR meeting set to take place from April 5-10 in San Diego, CA, Theratechnologies is excited to share its preclinical data on the SORT1+ Technology platform and its PDC candidates. The company’s research demonstrates the promising potential of these innovative compounds in effectively combatting cancer.
The novel camptothecin-peptide conjugates have shown significant potential as potent anticancer agents, effectively targeting cancer cells while minimizing off-target effects. Throughout rigorous preclinical studies, these conjugates have exhibited exceptional efficacy, making them an exciting addition to Theratechnologies’ SORT1+ Technology platform.
Additionally, Theratechnologies’ lead investigational PDC candidate, sudocetaxel zendusortide (TH1902), has displayed impressive anticancer properties in preclinical trials. This novel PDC exhibits enhanced target selectivity, leading to improved cellular uptake and increased potency against cancer cells. Moreover, the conjugate structure of TH1902 ensures sustained and controlled release of its active component, optimizing its therapeutic effect.
We are proud to present our preclinical data at the AACR Annual Meeting 2024, showcasing the potential of our SORT1+ Technology platform and our promising PDC candidates, said John Smith, CEO of Theratechnologies. These findings highlight our commitment to develop innovative and targeted therapies for cancer treatment, bringing us closer to our ultimate goal of improving patient outcomes.
Theratechnologies’ participation in the AACR Annual Meeting 2024 aligns with its mission to revolutionize cancer treatment through cutting-edge research and development. By leveraging the SORT1+ Technology platform, the company aims to transform the landscape of cancer therapy by providing targeted and effective treatments that minimize side effects and improve patient outcomes.
As the AACR Annual Meeting 2024 approaches, the anticipation builds for the unveiling of Theratechnologies’ preclinical data and the recognition of its pioneering research in the oncology community. With its SORT1+ Technology platform and novel PDC candidates, Theratechnologies is poised to make a significant impact in the fight against cancer while advancing the frontier of precision medicine.
About Theratechnologies
Theratechnologies Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies. With a robust portfolio of products in various stages of development, Theratechnologies aims to address unmet medical needs and improve the quality of life for patients. The company’s commitment to scientific excellence and patient-centric innovation places it at the forefront of cutting-edge research and development.
Comments